Latest Content

Immuto’s CEO discusses the benefits of SPCs for target discovery.

Merck’s decision to establish oncology as a standalone business unit reflects a strategic response to blockbuster concentration risk, lifecycle complexity, and intensifying competitive dynamics, as the company prepares for the anticipated loss of exclusivity of Keytruda and repositions organizational design as a lever for long-term value protection and growth.

The acquisition builds on the companies’ previous collaboration advancing anitocabtagene autoleucel (anito-cel).

The COVID-19 pandemic dramatically accelerated cancer-vaccine science by validating the mRNA technology at global scale.

Jay Bregman, CEO and co-founder of Andel discusses how FDA’s planned action against non-FDA-approved GLP-1 products could reshape competition in obesity and diabetes care.

BioNTech filed a patent infringement lawsuit against Moderna alleging unauthorized use of patented mRNA technology.

The judges ruled against tariffs levied using an emergency law.

FDA approves AstraZeneca’s fixed-duration, all-oral Calquence plus venetoclax regimen for first-line CLL and SLL in adults.

In this video episode, Pratap Khedkar, PhD, CEO of ZS, joins the Pharm Exec Podcast to discuss three distinct industry trends and strategy shifts converging at the moment amid the backdrop of US-driven global policy change.

The vaccine advisory committee’s meeting has yet to be rescheduled.

Study results showed that patients saw three years of remission while taking the medication.

Hims & Hers has agreed to acquire Australia-based Eucalyptus for up to $1.15 billion, expanding its international footprint across Australia, Canada, Germany and the U.K.

FDA is shifting its default standard for drug approvals, announcing that one adequate and well-controlled clinical trial will generally be sufficient for approvals.